A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer-Reference-Cited by-同舟云学术

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer

Published:2015-07 Issue:1 Volume:162 Page:146-159
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Dietlein Felix,Kalb Bastian,Jokic Mladen,Noll Elisa M.,Strong Alexander,Tharun Lars,Ozretić Luka,Künstlinger Helen,Kambartel Kato,Randerath Winfried J.,Jüngst Christian,Schmitt Anna,Torgovnick Alessandro,Richters André,Rauh Daniel,Siedek Florian,Persigehl Thorsten,Mauch Cornelia,Bartkova Jirina,Bradley Allan,Sprick Martin R.,Trumpp Andreas,Rad Roland,Saur Dieter,Bartek Jiri,Wolf Jürgen,Büttner Reinhard,Thomas Roman K.,Reinhardt H. Christian

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference16 articles.

1. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity;Barretina;Nature,2012

2. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints;Bartkova;Nature,2006

3. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes;Biankin;Nature,2012

4. Comprehensive molecular profiling of lung adenocarcinoma;Nature,2014

5. Cell death by mitotic catastrophe: a molecular definition;Castedo;Oncogene,2004

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases;Signal Transduction and Targeted Therapy;2024-07-12

2. Remodeling tumor‐associated macrophage for anti‐cancer effects by rational design of irreversible inhibition of mitogen‐activated protein kinase‐activated protein kinase 2;MedComm;2024-07

3. DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies;Blood;2024-05-23

4. Deciphering the role of KRAS gene in oncogenesis: Focus on signaling pathways, genetic alterations in 3’UTR, KRAS specific miRNAs and therapeutic interventions;Critical Reviews in Oncology/Hematology;2024-02

5. An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma;Blood Advances;2023-12-07